Latest Breaking News On - Talimogene laherparepvec - Page 1 : comparemela.com

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4-8, 2021. Overall survival (OS) data from the Phase 2 CodeBreaK 100 trial of LUMAKRAS™ (sotorasib), a potentially first-in-class KRAS

United statesPuerto ricoMegan foxStevens johnsonFluorouracil leucovorinTalimogene laherparepvecDavidm reeseAmerican society of clinical oncologyAdministration guidelinesZai labDrug administrationBeigene ltdExchange commissionZai lab shanghai coTherapeutics incEuropean union